Bone Treatment in Children with Osteogenesis Imperfecta
Author Information
Author(s): Futagawa Natsuko, Hasegawa Kosei, Miyahara Hiroyuki, Tanaka Hiroyuki, Tsukahara Hirokazu
Primary Institution: Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Hypothesis
Bisphosphonates would not only increase BMD but would also affect trabecular bone formation and the duration of BIS treatment would correlate with the TBS since BISs inhibit bone resorption.
Conclusion
BIS treatment increases the TBS, particularly in patients with moderate to severe OI compared with those with mild OI.
Supporting Evidence
- The TBS Z-score showed a significant positive correlation with treatment duration in the moderate to severe group.
- In the mild group, the aBMD and its Z-score were significantly positively correlated with treatment duration.
- The study found that BIS treatment increases BMD in patients with OI, but the effect on TBS varies by severity.
Takeaway
This study looked at how a medicine called bisphosphonates helps kids with a bone disease called osteogenesis imperfecta. It found that the medicine works differently depending on how severe the disease is.
Methodology
The study enrolled 29 children with OI, classified them by severity, and analyzed DXA images for TBS calculation.
Potential Biases
The participants were treated following different protocols, which could lead to bias.
Limitations
The study could not evaluate the TBS Z-score in patients aged <5 years and had a small sample size.
Participant Demographics
The study included 29 Japanese children with OI, classified into mild and moderate to severe groups.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website